Xilio Therapeutics Announces Preliminary Clinical Data From Phase I Trial of XTX101, a Tumor-Activated, FC-Enhanced Anti-CTLA-4, in Patients With Advanced Solid Tumors

Xilio Therapeutics, Inc. announced preliminary data from its Phase I clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.